Management and Outcomes of Major Bleeding During Treatment With Dabigatran or Warfarin

Authors:
  • AMAmmar Majeed
    Ammar Majeed
  • HHHun-Gyu Hwang
    Hun-Gyu Hwang
  • SCStuart J. Connolly
    Stuart J. Connolly
  • JEJohn W. Eikelboom
    John W. Eikelboom
  • MEMichael D. Ezekowitz
    Michael D. Ezekowitz
  • LWLars Wallentin
    Lars Wallentin
  • MBMartina Brueckmann
    Martina Brueckmann
  • MFMandy Fraessdorf
    Mandy Fraessdorf
  • SYSalim Yusuf
    Salim Yusuf

Abstract
Background—: The aim of this study was to compare the management and prognosis of major bleeding in patients treated with dabigatran or warfarin. Methods and Results—: Two independent investigators reviewed bleeding reports from 1034 individuals with 1121 major bleeds enrolled in 5 phase III trials comparing dabigatran with warfarin in 27 419 patients treated for 6 to 36 months. Patients with major bleeds on dabigatran (n=627 of 16 755) were older, had lower creatinine clearance, and more frequently used aspirin or non-steroid anti-inflammatory agents than those on warfarin (n=407 of 10 002). The 30-day mortality after the first major bleed tended to be lower in the dabigatran group (9.1%) than in the warfarin group (13.0%; pooled odds ratio, 0.68; 95% confidence interval, 0.46–1.01; P =0.057). After adjustment for sex, age, weight, renal function, and concomitant antithrombotic therapy, the pooled odds ratio for 30-day mortality with dabigatran versus warfarin was 0.66 (95% confidence interval, 0.44–1.00; P =0.051). Major bleeds in dabigatran patients were more frequently treated with blood transfusions (423/696, 61%) than bleeds in warfarin patients (175/425, 42%; P P P =0.01). Conclusions—: Patients who experienced major bleeding on dabigatran required more red cell transfusions but received less plasma, required a shorter stay in intensive care, and had a trend to lower mortality compared with those who had major bleeding on warfarin. Clinical Trial Registration—: URL: http://www.ClinicalTrials.gov . Unique identifiers: NCT00262600, NCT00291330, NCT00680186, NCT00329238 and NCT00558259.

This publication has 32 references indexed in Scilit: